More Americans with diabetes will get a break on their insulin costs in 2024.
Sanofi is joining the nation’s two other major insulin manufacturers in offering either price caps or savings programs that lower the cost of the drugs to $35 for many patients. The three drugmakers are also drastically lowering the list prices for their products.
The moves were announced in the spring, but some didn’t take effect until January 1.
Drugmakers have come under fire for years for steeply raising the price of insulin, which is relatively inexpensive to produce. The inflation-adjusted cost of the medication has increased 24% between 2017 and 2022, and spending on insulin has tripled in the past decade to $22.3 billion in 2022, according to the American Diabetes Association.
Some 8.4 million Americans rely on insulin to survive, and as many as 1 in 4 patients have been unable to afford their medicine, leading them to ration doses – sometimes with fatal ramifications, according to the association.
When people say free, they don’t mean completely free. They mean free at point of use for the patient, with the system funded by tax dollars like every other first world nation.
An example in the US would be the military. If you are in the military, either active or reserves, and need a prescription then it’s 100% free to you if you pick it up at a military pharmacy. That doesn’t mean that the manufacturer of the prescription is eating the cost, it means the federal government is using tax dollars to pay that on the back end and the military patient doesn’t pay out of pocket for it.
We could do that on a national scale for cheaper than what we collectively pay now for healthcare.